Stocktoria
BridgeBio Oncology Therapeutics, Inc. BBOT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-02-09
BridgeBio Oncology Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $121.2M | $73.1M | — |
| Operating income | -$145.8M | -$80.9M | -$41,692 |
| Income tax | $0 | $0 | — |
| Net income | -$134.0M | -$74.3M | -$41,692 |
| EPS (diluted) | $-4.30 | $-5756.41 | — |
| Operating cash flow | -$113.9M | -$55.0M | — |
| Free cash flow | -$114.5M | -$55.1M | — |
| Cash & equivalents | $373.7M | $30.9M | — |
| Total assets | $448.4M | $164.3M | $332,894 |
| Total liabilities | $37.3M | $19.6M | $396,463 |
| Shareholders' equity | $411.1M | -$178.6M | -$115.6M |
Source: SEC EDGAR filings · CIK 0001869105 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.